VANCOMYCIN AND LINEZOLID IN NOSOCOMIAL INFECTIONS CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCI


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Recent studies of the efficacy of vancomycin and linezolid in the treatment of patients with nosocomial infections caused by methicillin-resistant staphylococci have allowed a weighted comparative evaluation of these drugs.

全文:

受限制的访问

作者简介

N. Dmitrieva

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow

I. Petukhova

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow

Email: irinapet@list.ru

Z. Grigoryevskaya

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow

参考

  1. Белоусов Ю. Б., Филиппова О. В., Селютин О. А. и др. Сравнительная характеристика препаратов ванкомицина, зарегистрированных в Р.Ф. // Качественная клиническая практика. - 2009; 5: 1-13.
  2. Дехнич А. Терапия нозокомиальных стафилококковых инфекций в России - время менять стереотипы // Врач. - 2010; 10: 18-22.
  3. American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia // Am. J. Respir. Crit. Care. -2005; 17 (4): 338-416.
  4. Boselli E., Breilh D., Rimmele T. et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia // Crit. Care Med. - 2005; 33 (7): 1529-1533.
  5. Bounthavong M., Hsu D. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis // Curr. Med. Res. Opin. - 2010, 26 (2): 407-421.
  6. Brown J., Aitken S., van Manen R. Potential for linezolid-related blindness: a review of spontaneous adverse events reports // Pharmacotherapy. -2011; 31 (6): 585-590.
  7. Chan J., Pham T., Wong J. et al. Clinical outcomes of linezolid vs vancomycin in methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia. Retrospective analysis // J. Intensive Care Med. - 2011; doi: 10.1177/0885066610392893.
  8. Cruciani M., Gatti G., Lazzarini L. et al. Penetration of vancomycin into human lung tissue // J. Antimicrob. Chemother. - 1996; 38 (5): 865-886.
  9. Dandache P., Moise P., Orsini J. et al. Reduced biofilm production associated with increasing linezolid MICs among linezolid-resistant staphylococci // J. Antimicrob. Chemother. - 2009, 64: 1114-1118.
  10. Dodds T., Hawke C. Linezolid versus vacomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis) // ANZ J. Surg.- 2009; 79 (9): 629-635.
  11. Fowler V., Sexton D. Treatment of Staphylococcus aureus bacteriemia in adults. In: UpToDate, Rose B. (ed), UpToDate, Waltham M., 2009, Accessed July 23, 2009.
  12. Gales A., Sader H., Andrade S. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis // Intern. J. Antimicrob. Agents. - 2006; 27: 300-302.
  13. Garcia M., de la Torre M., Morales G. et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit // JAMA. - 2010; 303 (22): 2260-2264.
  14. Gluck T. Linezolid vs.vancomycin for soft-tissue infections // J. Watch Infect Dis. - 2005; 8: 6 (www.infectious-diseases.jwatch. org/cgi/content/full/2005/708/6).
  15. Itani K., Dryden M., Bhattacharyya H. et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissie infections proven to be caused by methicillin-resistant Staphylococcus aureus // Am. J. Surg. - 2010; 199 (6): 804-816.
  16. Jang H., Kim S., Kim K. et al. Salvage treatment for persistent methicillin-resistant Staphylococus aureus bacteriemia: efficacy of linezolid with or without carbapenem // Clin. Infect. Dis. - 2009; 49: 395-401.
  17. Kalil A., Murthy M., Hermsen E. et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis // Crit. Care Med. - 2010: 38 (9): 1802-1808.
  18. Kollef M., Shorr A., Tabak Y. et al. Epidemiology and outcomes of healthcare-associated pneumonia: results from a large US database of culture-positive pneumonia // Chest. - 2005; 128 (6): 3854-3862.
  19. Lamer C., de Beco V., Soler P. et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients // Antimicrob Agents Chemother. - 1993; 37 (2): 281-286.
  20. Luna C., Bruno D., Garcia-Morato J. et al. Effect of linezolid compared with vancomycin in methicillin-resistant Staphylococcus aureus severe pneumonia in piglets // Chest 2009; 135 (6): 1564-1571
  21. Mazzariol A., Lo Cascio G., Kocsis E. et al. Outbreak of linezolid-resistant Staphylococcus haemolyticus in an Italian intensive care unit // Eur. J. Clin. Microb. Infect. Dis. - 2011; DOI 10/1007/s10096-011-1343-6.
  22. Que Y.-A., Morellion P. Staphylococus aureus (including Staphylococcal toxic shock). Chapter 195. - In: Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 7-th edition. Eds: Mandell G., Bennett J., Dolin R. Churchill Livingstone. - Elsevier, 2010. - P. 2543-2578.
  23. Rodriguez-Aranda A., Daskalaki M., Villar J. Et al. Nosocomial spread of linezolid-resistant Staphylococcus haemolyticus infections in intensive care unit // Diagn Microbiol Infect Dis. - 2009; 63: 398-402.
  24. SENTRY Antimicrobial Surveillance Programm // Diagn Microbiol Infect Dis. - 2000; 43: 303-309.
  25. Shorr A., Kunkel M., Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteriemia: pooled analysis of randomized studies // J. Antimicrob Chemother. - 2005; 56: 923-929.
  26. Stevens D., Herr D., Lampiris H. et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections // Clin. Infect. Dis. - 2002; 34: 1481-1490.
  27. Styers D., Sheehan D., Hogan P. et al. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States // Ann. Clin. Microbiol. Antimicrob. - 2006; 5: 2.
  28. Tarazona R., Padilla T., Gomez J. et al. First report in Spain of linezolid nonsusceptibility in a clinical isolate of Staphylococcus haemolitycus // Intern. J. Antimicrob. Agents. - 2007; 30: 274-285.
  29. Walkey A. O'Donnell M., Wiener R. Linezolid versus glycopeptide antibiotics for the treatment of suspected meticillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials // Chest. -2011; 139 (5): 1148-1155.
  30. Weigelt J., Itani K., Stevens D. et al. Linezolid versus vancomycin in theatment of complicated skin and soft tissue infections // Antimicrob. Agents. Chemother. - 2005; 49 (6): 2260-2266.
  31. Wilcox M., Tack K., Bouza E. et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study // Clin. Infect. Dis. - 2009; 48: 2003-2012.
  32. Wunderlink R., Rello J., Cammarata S. et al. Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia // Chest. - 2003; 124 (5): 1789-1797.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2012